Details for Patent: 7,351,834

Which drugs does patent 7,351,834 protect, and when does it expire?

Patent 7,351,834 protects STIVARGA and is included in one NDA.

This patent has one hundred and thirteen patent family members in fifty-one countries.

Summary for Patent: 7,351,834

Title:	.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:	This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s):	Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy (Hyogo, JP), Scott; William (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert (North Haven, CT)
Assignee:	Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:	09/889,227
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,351,834
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,351,834

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	STIVARGA	regorafenib	TABLET;ORAL	203085-001	Sep 27, 2012		RX	Yes	Yes				Y

Foreign Priority and PCT Information for Patent: 7,351,834

PCT Information
PCT Filed	January 12, 2000	PCT Application Number:	PCT/US00/00648
PCT Publication Date:	July 20, 2000	PCT Publication Number:	WO00/42012

International Family Members for US Patent 7,351,834

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	035310
Argentina	077485
Austria	321027
Austria	460398
Austria	520663
Austria	538794
Austria	556713